

PET-OP

05-27-04

DACB

RECEIVED

JUN 02 2004

PATENT

Attorney Docket No.: 4343.214-US

OFFICE OF PETITIONS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Re Application of: Jensen et al.

Serial No.: 09/767,981

Group Art Unit: 1647

Filed: January 23, 2001

Examiner: David Romeo

Confirmation No. 2751

For: Protracted GLP-1 Compositions

PETITION TO REVIVE UNDER 37 C.F.R. 1.137 (b)

MS: Petitions
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The above-identified application was abandoned for failure to prosecute. Applicants respectfully state that the delay was unintentional and petition that the application be revived and reinstated as a pending application. Applicants further state that the entire delay in filing the required reply from the due date for the reply until the filing of a grantable petition pursuant to 37 CFR 1.137 (b) was unintentional.

A continuation application accompanies this petition.

Please charge the amount of \$1,330 [the fee under 1.17 (m)] to cover the cost of this Petition and charge any additional fees which may be required by this or any other related paper, or credit any overpayment to Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

05/28/2004 SDENR001 00000076 141447 09767981
01 FC:1453 1330.00 DA

Attorney Docket No.: 4343.214-US
Express Mail Label No.: EV 409530797 US

Applicants request favorable action on this request.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this response or application.

Respectfully submitted,

Date: May 26, 2004

Richard W. Bork
Richard W. Bork, Reg. No. 36,459
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

Use the following customer number for all correspondence regarding this application.

23650

PATENT TRADEMARK OFFICE